News | Renal Denervation | August 31, 2017

SPYRAL HTN-OFF MED Study Results Show Efficacy, Safety of Renal Denervation

Late-breaking ESC results encourage Medtronic to move forward with renal denervation pivotal trial

SPYRAL HTN-OFF MED Study Results Show Efficacy, Safety of Renal Denervation

August 31, 2017 — Medtronic plc announced its intent to move forward with a new renal denervation pivotal trial following positive first results from a sham-controlled study in patients with high blood pressure. Investigators of the SPYRAL HTN-OFF MED Study found statistically significant and clinically important blood pressure reductions in the patients treated with renal denervation (RDN) across both office and ambulatory systolic and diastolic measurements. The data in the first 80 patients enrolled in the study at three months were presented in a late-breaking clinical trial session at the European Society of Cardiology (ESC) meeting, Aug. 26-30 in Barcelona, Spain and published simultaneously in The Lancet.

“Based on the clinical results presented at ESC, we are confident that the SPYRAL HTN-OFF MED Study has successfully demonstrated the treatment effect of RDN,” said co-principal investigator (PI) and presenter of the data at ESC, Prof. Michael Böhm, M.D., Ph.D., chairman, Department of Internal Medicine, University of Saarland in Homburg/Saar, Germany. “With consistent and significant drops across ambulatory and office-based blood pressure — including both systolic and diastolic measurements — we are confident to be moving forward with a pivotal trial so that doctors and patients may have an alternative approach to lowering blood pressure.”

The initial three-month data found that patients who underwent renal denervation had their office systolic blood pressure (OSBP) decline an average 10 mm Hg, resulting in a 7.7 mm Hg difference with the patients in the sham control arm (p=0.016), and their diastolic blood pressure declined an average 5.3 mm Hg, resulting in a 4.9 mm Hg difference with the sham control arm (p=0.008). With a systolic blood pressure difference of 7.7 mm Hg between the two groups, a recent meta-analysis published in The Lancet associated that decrease with a relative risk reduction of approximately 20 percent for major cardiovascular events, including heart attack and stroke.

In SPYRAL HTN OFF-MED renal denervation patients, the 24-hour systolic ambulatory blood pressure (ABPM) declined 5.5 mm Hg, resulting in a 5 mm Hg difference from the sham control arm (p=0.041), and the diastolic AMBP declined 4.8 mm Hg, resulting in a 4.4 mm Hg difference from the sham control arm (p=0.002). Additionally, there were no reported cases of new or worsening renal failure, vascular complications or other major adverse events, confirming the safety of the RDN procedure — even with a revised procedural approach that extended ablations into the kidney’s branch arteries and an increase in total number of ablations compared with previous RDN trials.

“After SYMPLICITY HTN-3, we learned a lot about the procedure itself, medication adherence and which patients may have less response to the RDN procedure — these insights have been incorporated into the revised clinical approach in the SPYRAL HTN program,” said co-PI David Kandzari, M.D., director of interventional cardiology and chief scientific officer, Piedmont Heart Institute in Atlanta, Ga. “With this new approach and protocol design, coupled with new technology that allows more consistent circumferential treatment and easier access into the distal anatomy, based on these compelling results we are confident that we’ve appropriately addressed the issues in previous renal denervation trials.”

The SPYRAL HTN-OFF MED Study evaluated RDN in the absence of any antihypertensive medications compared to a sham-controlled population to isolate its effect on blood pressure reduction. The study enrolled 353 patients who were either drug-naïve or willing to discontinue medication for four months, with mild-to-moderate hypertension (OSBP equal to or more than 150 mm Hg and less than 180 mm Hg) at 24 centers in the U.S., Europe, Japan and Australia. Prior to randomization, patients were required to stop taking their antihypertensive medication during a period of three to four weeks, known as a medication washout. During the washout period and the three months following randomization, patients were monitored to ensure their blood pressure would not exceed 180mm Hg.

“These results are extremely encouraging for the more than 50 percent of hypertension patients who become non-adherent to their medications within one year of initiating therapy,” said co-PI Raymond Townsend, M.D., director of the hypertension program, University of Pennsylvania. “The societal implications are potentially huge as well, as high blood pressure contributes more than 500 billion dollars in direct costs to our healthcare systems globally.”

Unlike SYMPLICITY HTN-3, where patients self-reported adherence, and change in medications occurred among 40 percent of patients, the SPYRAL HTN-OFF MED Study limited that variability, as patients remained off their medication throughout the duration of the study as confirmed by serum and urine testing for antihypertensive medication. Additionally, the aftermath of SYMPLICITY HTN-3 revealed new anatomical insights showing that renal nerves are easier to access when the catheter treats the renal artery segments located close to the kidney. While SYMPLICITY HTN-3 only averaged five ablations in the main renal artery and no ablations in the branch arteries, the flexible design and low profile of the investigational Symplicity Spyral system achieved an average of 10 main renal artery and 13 branch artery ablations per kidney.

The SPYRAL HTN-OFF MED study is part of the SPYRAL HTN Global Clinical Trial Program and accompanies the SPYRAL HTN-ON MED study as two global, prospective, randomized, sham-controlled trials conducted simultaneously by hypertension experts and experienced proceduralists to investigate the impact of renal denervation both in the absence of and in the presence of antihypertensive medications. The clinical program utilizes Medtronic's next-generation renal denervation technology, composed of the flexible, 6 Fr guide catheter-compatible, Symplicity Spyral multi-electrode renal denervation catheter and Symplicity G3 renal denervation RF (radiofrequency) generator.

The Symplicity Spyral system is investigational in the United States and Japan.

Watch the VIDEO "Device Therapies to Treat Hypertension," an interview with Krishna Rocha-Singh, M.D., at TCT 2016.

Read the article "Medtronic Announces Spyral HTN Global Clinical Trial Program for Renal Denervation."

For more information:

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init